Clinical trials: Alzheimer Disease (AD)
Alzheimer Dementia (AD), Caregivers
MUSic Listening Impact on QUality of Life, Brain and Burnout of ALzheimer' Patients Informal Caregivers
Although life expectancy is increasing, the risk of dependence and/or loss of autonomy is increasing too with ageing. Alzheimer's disease affects many people and this kind of disease is constantly growing.
- Trial name
- MUSIQUAL+ (NCT07159542)
- Testing
- listening intervention, Neuropsychology assessment, brain imaging examination
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
Alzheimer Disease, Battery
Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs.
- Trial name
- PharmacogWP3 (NCT01487395)
- Testing
- Donepezil .
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer's Disease, Mild Cognitive Impairment
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
This study compares different music therapy (MT) experiences and their impact on memory and language in patients with Alzheimer's disease and Mild Cognitive Impairment.
- Trial name
- NCT04666077
- Testing
- Home-based MT through Supervised, Supported Singing (H3S), Individualized Music Therapy (IMT), Attention Control (AtCon)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).
- Trial name
- TEPAmy (NCT06467981)
- Testing
- Retrospective study
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Central Hospital, Nancy, France
Alzheimer Disease
Cognitive Decline in AD
There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors.
- Trial name
- NCT03946930
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
AD - Alzheimer's Disease, Mild Cognitive Impairment
NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK
Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65.
- Conditions
- AD - Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition, Dementia
- Trial name
- NCT07347574
- Testing
- Observational
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Hong Kong University of Science and Technology
Alzheimer Disease, Gut Biome
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing AD in the future. Past studies have shown the presence of serum indicators correlated with gut biome dysfunction in AD patients.
- Trial name
- NCT05601856
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Alzheimer Disease
Locus-coeruleus Function in Normal Elderly and AD Risk
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife.
- Trial name
- LEAD (NCT04403165)
- Testing
- Nocturnal polysomnography (NPSG), Lumbar Puncture (LP), PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when…
- Trial name
- INTERCEPT-AD (NCT04931459)
- Testing
- ACU193
- Where
- 17 sites in United States
- Volunteers
- 65 people
- Sponsor
- Acumen Pharmaceuticals
Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease
Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment
Age-related cognitive decline is unavoidable. However, recent results of neuroplasticity-based research show that neuroplasticity-based training and physical activity might have the potential to decelerate or even reverse effects…
- Trial name
- NCT01061489
- Testing
- auditory discrimination training, physical movement training
- Where
- 2 sites in Germany
- Volunteers
- 65 people
- Sponsor
- University of Konstanz
Mild Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Effect of AQW051 in Patients With Memory Impairment
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure…
- Trial name
- NCT00582855
- Testing
- AQW051
- Where
- 12 sites in Canada, South Africa and 1 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.
- Trial name
- NCT01656525
- Testing
- Gantenerumab
- Where
- 5 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Chugai Pharmaceutical
Alzheimer Disease
A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers
The objective of this study is to compare the effectiveness of 2 intervention delivery strategies for increasing moderate physical activity (MPA), real-time group video conferencing (RGV) vs.
- Trial name
- NCT04102514
- Testing
- Real-time Group Video, Enhanced Usual Care
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of Kansas
Dementia, Traumatic Brain Injury
Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI
To reduce care resistant behaviors (CRB) among people with dementia residing in nursing homes, to a distance-learning education, training, and coaching program for family caregivers of people with dementia or TBI; assess the…
- Trial name
- NCT03734289
- Testing
- Caregiver Coaching
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Alzheimer's Disease
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
- Trial name
- DISCOVER (NCT02925650)
- Testing
- Posiphen
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Annovis Bio Inc.
Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
Alzheimer's disease causes progressive memory and cognitive decline, driven in part by the buildup of a protein called β-amyloid in the brain.
- Trial name
- NCT07456462
- Testing
- MRI assessment and blood sample collection
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Hippocampal Hyperactivation, Prodromal Alzheimer Disease
Levetiracetam for Persons at Risk for Alzheimer's Disease
The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce elevated brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease…
- Trial name
- ALEVIATE-2 (NCT07477431)
- Testing
- Levetiracetam (LEV)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre